Corrigendum to "Osimertinib As First-line Treatment for Elderly Patients with Advanced EGFR Mutation-positive Non-small-cell Lung Cancer in a Real-world Setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426]